The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer

Breast Cancer Research

Volumn 15, Issue 1, 2013, Pages

  Peurala, Emmi ^a,b   Koivunen, Peppi ^b   Haapasaari, Kirsi Maria ^a,b   Bloigu, Risto ^b   Jukkola Vuorinen, Arja ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN P16; CCND1 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84872400379     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3376     Document Type: Article

References (40)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330. 10.1016/0092-8674(95)90385-2, 7736585.
2. Sherr CJ. Cancer cell cycles. Science 1996, 274:1672-1677. 10.1126/science.274.5293.1672, 8939849.
3. Massagué J. G1 cell-cycle control and cancer. Nature 2004, 432:298-306. 10.1038/nature03094, 15549091.
4. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D2 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007, 98:629-635. 10.1111/j.1349-7006.2007.00449.x, 17359287.
5. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011, 11:558-572.
6. Li J, Poi M, Tsai M-D. Regulatory mechanisms of tumor suppressor P16INK4A and their relevance to cancer. Biochemistry 2011, 50:5566-5582. 10.1021/bi200642e, 3127263, 21619050.
7. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16ink4a expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 2011, 10:2497-2503. 10.4161/cc.10.15.16776, 21775818.
8. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993, 8:2127-2133.
9. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 2010, 9:689-699. 10.4161/cc.9.4.10611, 20107323.
10. Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K, Caceres JF, Dubus P, Malumbres M, Barbacid M. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007, 448:811-815. 10.1038/nature06046, 17700700.
11. Thoms HC, Dunlop MG, Stark LA. CDK4 inhibitors and apoptosis. a novel mechanism requiring nucleolar targeting of RelA. Cell Cycle 2007, 6:1293-1297. 10.4161/cc.6.11.4312, 17525529.
12. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006, 15:718-727. 10.1016/j.breast.2006.02.005, 16675218.
13. Yang WI, Zukerberg LR, Motkura T, Arnold A, Harris NL. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994, 145:86-96. 1887308, 7518196.
14. Boström P, Söderström M, Palokangas T, Vahlberg T, Collan Y, Carpen O, Hirsimäki P. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes 2009, 2:140-147. 10.1186/1756-0500-2-140, 2716358, 19615042.
15. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995, 375:503-506. 10.1038/375503a0, 7777060.
16. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001, 264:42-55. 10.1006/excr.2000.5149, 11237522.
17. Chae SW, Sohn JH, Kim D-H, Choi YJ, Park YL, Kim K, Cho YH, Pyo J-S, Kim JH. Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications. Yonsei Med J 2011, 52:445-453. 10.3349/ymj.2011.52.3.445, 3101063, 21488187.
18. Bohn OL, Fuertes-Camilo M, Navarro L, Saldivar J, Sanchez-Sosa S. p16INK4a expression in basal-like breast carcinoma. Int J Clin Exp Pathol 2010, 3:600-607. 2907122, 20661408.
19. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008, 10:R75. 10.1186/bcr2142, 2614508, 18782450.
20. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, Lyon: IARC Press, Tavassoli FA, Devilee P.
21. Peurala E, Karppinen P, Haapasaari KM, Bloigu R, Jukkola-Vuorinen A. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat 2011, 133:179-188.
22. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004, 10:4793-4798. 10.1158/1078-0432.CCR-0428-03, 15269154.
23. Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M, Landberg G. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res 2012, 14:R57. 3446392, 22475046.
24. Jirström K, Stendahl M, Rydén L, Kronblad A, Bendahl PO, Stål O, Landberg G. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005, 65:8009-8016.
25. Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M, Austrian Breast and Colorectal Cancer Study Group Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 2008, 14:1767-1774. 10.1158/1078-0432.CCR-07-4122, 18347178, Austrian Breast and Colorectal Cancer Study Group.
26. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 Is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000, 6:1891-1895.
27. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, Capparelli C, Giordano C, Giordano F, Maggiolini M, Andò S. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element. Nucleic Acids Res 2010, 38:5351-5365. 10.1093/nar/gkq278, 2938215, 20421209.
28. An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of Cdk4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999, 154:113-118. 10.1016/S0002-9440(10)65257-1, 1868599, 9916925.
29. Reddy HK, Mettus RV, Rane SG, Grana X, Litvin J, Reddy EP. Cyclin-dependent kinase 4 expression is essentiel for neu-induced breast tumorgenesis. Cancer Res 2005, 65:10174-10178. 10.1158/0008-5472.CAN-05-2639, 16288002.
30. Reddy HK, Graña X, Dhanasekaran DN, Litvin J, Reddy EP. Requirement of Cdk4 for v-Ha-ras-Induced breast tumorigenesis and activation of the v-ras-Induced senescence program by the R24C mutation. Gene Cancer 2010, 1:69-80.
31. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003, 114:323-334. 10.1016/S0092-8674(03)00570-1, 12914697.
32. Pinto AP, Degen M, Villa LL, Cibas ES. Immunomarkers in gynecologic cytology: the search for the ideal 'biomolecular Papanicolaou test'. Acta Cytol 2012, 56:109-121. 10.1159/000335065, 22378072.
33. Guihard S, Jung AC, Noël G. High-risk human papilloma virus associated oropharynx squamous cell carcinomas: clinical, biological implications and therapeutical perspectives. Cancer Radiother 2012, 16:34-43. 10.1016/j.canrad.2011.11.001, 22316562.
34. Yin M, Bastacky S, Parwani AV, McHale T, Dhir R. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol 2008, 39:527-535. 10.1016/j.humpath.2007.08.005, 18234280.
35. Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution. Patholog Res Int 2011, 2011:903202.
36. Milde-Langosch K, Bamberger A-M, Rieck G, Kelp B, Löning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001, 67:61-70. 10.1023/A:1010623308275, 11518467.
37. Zhang J, Lu A, Li L, Yue J, Lu Y. p16 modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells. Cancer Invest 2010, 28:588-597. 10.3109/07357900903286941, 2881182, 20307196.
38. Zygmunt A, Tedesco VC, Udho E, Krucher NA. Hypoxia stimulates p16 expression and association with cdk4. Exp Cell Res 2002, 278:53-60. 10.1006/excr.2002.5564, 12126957.
39. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008, 30:393-402. 10.1016/j.molcel.2008.04.009, 18498744.
40. Högel H, Rantanen K, Jokilehto T, Grenman R, Jaakkola PM. Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One 2011, 6:e27112. 10.1371/journal.pone.0027112, 3210766, 22087251.